p53 peptide

  • Description

  • Application Data

Description

Antigenic peptide of p53, a tumour suppressor and DNA binding protein that regulates transcription

See full description

Application Data

Catalogue number crb1200508
Antibody p53 peptide
Antigen Peptide p53 peptide
Protein ID UniProtKB - P04637
Aliases tumour protein p53, cellular tumour antigen p53, phosphoprotein p53, tumour suppressor p53, antigen NY-CO-13, transformation-related protein 53 (TRP53)
Cross-Reactivity Human
Target Protein Species Human
Storage Stabilisers -20°C
Specificity Protein
Storage -20°C
Citations

Cheok, C. and Lane, D. (2017). Exploiting the p53 Pathway for Therapy. Cold Spring Harb Perspect Med, 7(3), a026310. PMID: 28193768

 

Kastenhuber, E. and Lowe, S. (2017). Putting p53 in Context. Cell, 170(6), 1062-1078. PMID: 28886379

References

Cheok, C. and Lane, D. (2017). Exploiting the p53 Pathway for Therapy. Cold Spring Harb Perspect Med, 7(3), a026310. PMID: 28193768

 

Kastenhuber, E. and Lowe, S. (2017). Putting p53 in Context. Cell, 170(6), 1062-1078. PMID: 28886379

Material Safety Data Sheet (MSDS)

p53 is a sequence-specific DNA binding protein that regulates transcription. p53 is maintained at low levels in normal cells through mouse double minute 2 (MDM2) mediated degradation, however it is stabilised by phosphorylation and thus accumulates in response to cellular stresses such as DNA damage and replication stress. When p53 accumulates it promotes cell cycle arrest and apoptosis, thereby reducing the risk of propagating mutations. p53 mediates the DNA damage-induced G1 phase checkpoint, partly via its ability to transcriptionally activate the p21 cyclin-dependent kinase inhibitor gene. Activation of p21 triggers cell cycle arrest to allow for DNA repair prior to further cell division. p53 therefore acts as a tumour suppressor and inactivating mutations in the human p53 gene TP53 are common in many cancers

p53 peptide

Cat No.Pack SizePriceQty.
100µg£95.00
Bulk Quote